In the BioHarmony Drug Report Database
Lomefloxacin
Maxaquin, Quinsair (lomefloxacin) is a small molecule pharmaceutical. Lomefloxacin was first approved as Maxaquin on 1992-02-21. It is used to treat bronchitis, escherichia coli infections, klebsiella infections, proteus infections, and pseudomonas infections amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections.
Trade Name
|
Quinsair |
|---|---|
Common Name
|
lomefloxacin |
ChEMBL ID
|
CHEMBL561 |
Indication
|
bronchitis, cystic fibrosis, escherichia coli infections, klebsiella infections, proteus infections, pseudomonas infections, respiratory tract infections, staphylococcal infections, streptococcal infections, urinary tract infections |
Drug Class
|
Antibacterials (quinolone derivatives) |
Image (chem structure or protein)